Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
May 8, 2023
Earnings Call Speaker Segments
Zack Kubow
executiveThanks a lot, operator, and good afternoon to all of you. We appreciate your participation in today's call covering Corvus Pharmaceuticals' business update and financial results for the first quarter of 2023. Here with us to go over the results and business updates are Richard Miller, our Chief Executive Officer; Leiv Lea, Chief Financial Officer; James Rosenbaum, Senior Vice President of Research; and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team will begin with some prepared remarks, and after that we'll take questions. I want to remind everyone that both the comments management makes today and the responses to questions will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q, filed with the SEC today, as well as other filings the company makes with the SEC from time to time. Except where the law requires it, the company assumes no obligation to publicly update or revise any forward-looking statements; with that, I'd like to hand the call over to Leiv Lea.
Leiv Lea
executiveThanks, Zack. To kick things off, I'll give a brief review of how our finances looked in the first quarter of 2023, and after that I'll hand things over to Richard for an update on the business. When it came to research and development, our expenses for the first quarter of 2023 came to $4.6 million, versus $5.1 million during the same period in 2022. That $0.5 million drop was mostly tied to reduced costs for clinical trials and drug manufacturing. We posted a net loss of $7.9 million in the first quarter of 2023, and that figure included a $1.7 million non-cash loss tied to Angel Pharmaceuticals, compared with a net loss of $8.3 million, which included a $1.0 million non-cash loss tied to Angel during the same period in 2022. Total stock compensation expense came to $0.5 million in the first quarter of 2023, versus $0.7 million during the same period in 2022. As of March 31, 2023, Corvus held cash, cash equivalents and marketable securities amounting to $34.5 million, compared with $42.3 million as of December 31, 2022. Going forward, our expectation remains that net cash used in operating activities for the full year 2023 will land somewhere between 19 and $22 million. At the midpoint, that represents a 24% decrease from 2022, which shows how we keep concentrating on carefully managing our cash burn rate by zeroing in on our most promising opportunities and setting up collaborations that assist in supporting development of our product candidates. Given this trend, along with our focus on CPI-818, we believe our cash will give us runway into 2024. Now I'll pass the call to Richard, who will go into more detail about our strategy and plans.
Richard Miller
executiveThanks, Leiv, and hello to everyone this afternoon. We appreciate you being with us on today's call about our business update. Our attention remains fixed on moving CPI-818, the ITK inhibitor we're developing, forward toward what could become a registration Phase 3 randomized study in T cell lymphoma. It's our view that this first-in-class agent could serve as a significant new therapeutic choice for individuals battling relapsed peripheral T cell lymphoma, or PTCL, and might additionally offer a platform possibility spanning many cancer types and immune-related conditions. Regarding recent results with 818, several key near-term milestones stand out. First, enrollment remains strong in the Phase 1/1b study we're currently running, which now incorporates the biomarker we added not long ago, based on absolute lymphocyte count, or ALC. The information we're gathering keeps looking promising, with meaningful objective responses seen among refractory PTCL patients. Second, we'll be sharing further interim data from our Phase 1/1b T cell lymphoma study at the International Conference on Malignant Lymphoma taking place in Lugano, Switzerland in mid-June. During that event, we'll also share biopsy and blood data from patients that back up our proposed novel mechanism of action, which we think broadens the possible clinical uses past T cell lymphoma into solid tumors. Also, item three: we intend to meet with the FDA in the back half of this year — probably Q3 — so we can discuss how a registration Phase 3 study of CPI-818 in relapsed T cell lymphoma should be designed. As things stand, our expectation is that this will be a randomized trial with about 150 patients, comparing CPI-818 as a monotherapy against chemotherapy agents that represent the standard of care. The primary endpoint we have in mind is progression-free survival. Item four: if that FDA discussion turns out productive, we want to reach a point where 818 is Phase 3 ready, and that means getting the study underway before this year is over. And number five: fresh data that was presented at AACR indicates that when you block ITK selectively, it ramps up the immune system's ability to fight tumors—including solid tumors—and it achieves this through previously unknown immune pathways. During the Whistler Global Summit on Hematologic Malignancies that took place recently, Dr. John Reneau—who works as a hematologist specializing in lymphoma at the Ohio State University Comprehensive Cancer Center and serves as one of the investigators on the clinical trial for our 818—presented interim findings from that study. Those findings encompassed response data collected up to February 15, 2023, which we already went over during our call for the fourth quarter. In brief: out of 13 patients who were evaluable for tumor response, 4 experienced durable responses. Dr. During Reneau's portion of the call, additional data came forward supporting the minimum ALC biomarker threshold we recently put in place, which we anticipate will help select a population more likely to benefit from 818 treatment. According to that fresh evidence, ALC predicted how patients would respond to 818, while showing no relationship to outcomes from the prior chemotherapy regimens those patients had received before beginning 818. This pointed to the conclusion that the absolute lymphocyte count biomarker's positive predictive value was not simply a matter of enrolling patients who were already doing better. We have just updated our clinical results from the Phase 1/1b study. As of May 1st, a total of 28 patients had received doses at the optimal 200 milligram BID level, and among those, tumor response could be evaluated in 19. Looking at what we've seen so far: there are 2 complete responses, 1 nodal complete response, and 3 partial responses. Two of the patients who showed a partial response remain on treatment and are faring quite well. In total, 9 patients are still on therapy, and 5 of them have not yet had their tumor response evaluated; looking at those with an ALC above 900, objective tumor responses were seen in 6 of 13, which includes complete and partial responses, while disease control was achieved in 11 of 13 when you count CR, PR, and stable disease. For the 6 patients with an ALC below 900, 06, there were no responses at all. When it comes to median progression-free survival, the figure is 19.9 months for those with ALC above 900, compared with 2.1 months for those below 900. Naturally, every newly enrolled patient must have an absolute lymphocyte count above 900. The stronger responses among patients whose ALC is greater than 900 line up with our data that stimulating the immune response against the tumor adds to the activity of CPI-818. These results encourage us, and we'll keep enrolling patients so we can confirm and extend the findings. I'd also like to say a word about safety. The 200 milligram BI dose equals 1/3 of the top dose of 600 milligrams BID that was studied in the trial. We've demonstrated that the 200-milligram dose attained nearly complete ITK target occupancy. No dose-limiting toxicities occurred in any dose group, 600 milligrams BID included. We believe this medication has a favorable tolerability profile and ought to pair readily with alternative forms of oncology treatment. In April, our scientists shared fresh preclinical findings during the American Association for Cancer Research annual meeting, which back the idea of going after ITK as a novel strategy in cancer immunotherapy — this includes the possibility of addressing solid tumors alongside hematologic malignancies. Based on those findings, CPI-818 enhanced the immune reaction against multiple murine tumors, including colon, renal, melanoma, plus T and B cell lymphoma models. On top of that, 818 was demonstrated to increase infiltration of T effector cells into tumors and to strengthen the cytolytic capability of killer T cells. Additional results indicate that 818 reduces T cell exhaustion—a state that arises after prolonged antigen stimulation reprograms T cells and renders them ineffective. According to newer data, 818 is also capable of turning already exhausted T cells back into active T effector cells that regain their ability to kill. I'd like to restate the main results from our continuing Phase 1 study in T cell lymphoma, along with our latest preclinical information, since these findings point to a substantial broad opportunity for 818. Our view is that selectively inhibiting ITK could offer a fresh route in cancer immunotherapy, working through a novel mechanism that involves, first, inducing Th1 skewing. #2, increased infiltration of CD8 T effector cells into the tumor. Third, CD8 cells show greater cytolytic capability. And fourth, T cell exhaustion is reduced and reversed. Plus, we keep broadening our intellectual property around CPI-818 and how it can be used to treat cancers and autoimmune diseases; our view is that our IP position for 818 is strong, and we don't know of any other selective ITK inhibitors in clinical development right now. Composition-of-matter patents have already been granted in the U.S., Japan, Europe, China and additional countries. Moving quickly to the programs run by our partners. Right now, patients are being enrolled by the Kidney Cancer Research Consortium, which the University of Texas MD Anderson Cancer Center leads, in a Phase 1b/2 clinical trial. That study is testing ciforadenant as a potential first-line treatment for metastatic renal cell cancer, administered in a triplet combination with ipilimumab and nivolumab. Keep in mind that this is a single-arm, open-label trial, which means we anticipate gaining an early sense of how well it works. Based on the schedule we're working with right now, we expect that the first set of results from this study could come in before 2023 wraps up. As for mupadolimab, Angel Pharmaceuticals, our collaborator, is currently signing up participants for a Phase 1/1b study in China. That trial is evaluating mupadolimab both as a standalone treatment and alongside pembrolizumab in individuals with relapsed/refractory non-small cell lung cancer as well as head and neck squamous cell cancers. To close things out, we feel Corvus holds a distinctive position because we've made CPI-818 our top priority — it's the ITK inhibitor furthest along in development. Our entire focus is on 818, and our confidence keeps growing about how it performs across a wide spectrum of conditions, spanning cancers and autoimmunity. The findings we have, along with papers that came out lately from other groups, are making it clear how essential ITK is when it comes to controlling the immune system. T cell lymphoma, the first condition we're going after, is an area where patients truly lack options, and it could give us a route toward approval. We're building the case that ITK matters as a target worth pursuing for treatment. Looking ahead, we have several important milestones for our programs. First, we're continuing to enroll patients in the Phase 1/1b study of CPI-818 at the 200 milligram BI dose, and that includes using our new biomarker, absolute lymphocyte count. Second, we'll be presenting updated results from the CPI-818 Phase 1 T cell lymphoma trial at Lugano in June. Third, we'll be meeting with the FDA in the third quarter to talk about a randomized Phase 3 trial. And finally, for the programs run by our partners, we expect interim data from the ciforadenant trial before the end of 2023. We're eager to share updates on all of these key initiatives over the next few quarters. At this point, I'll hand the call over to the operator so we can begin the question-and-answer session.
Aydin Huseynov
analystNice work, Richard, and to the whole team, on this update. It looks as though — I'd simply like to verify — there are 2 additional responses, partial ones, coming from the new data batch?
Richard Miller
executiveLet me check — yes, 2 additional responses.
Aydin Huseynov
analystIf we look back at the last update call we held at March's close, isn't that right?
Richard Miller
executiveThat's right.
Aydin Huseynov
analystLet me ask about progression-free survival. You said 19.9 months. How many patients was that calculated from? Can you give us some additional clarity there?
Richard Miller
executiveThat figure comes from 13 patients.
Aydin Huseynov
analystAbout the FDA meeting, I believe we have somewhat better clarity now. You said this time it will take place during the third quarter. So what are you expecting from that meeting? You're planning a randomized trial of 150 patients. Beyond what you've already planned, do you anticipate any new specifics? That is, 1:1 randomization or a different randomization scheme, and the primary endpoint of PFS. Do you think any surprises could emerge from that meeting?
Richard Miller
executiveNo surprises are anticipated on my end. Our protocol, I believe, is quite straightforward. It is a randomized controlled trial. At this meeting, we're looking for agreement that this trial has been designed correctly and that, if the results are positive, it would back the product's registration for T cell lymphoma. The topics we'd like to raise with them, in my view, cover how standard therapies for the control arm get selected. So, as I said, it will be 818 given as monotherapy against a standard therapy for T cell lymphoma. Right now we're thinking roughly 3 drugs would be part of that. As you're aware, Belinostat and Pralatrexate hold approval for relapsed T cell lymphoma. Also, there's likely to be one more medication brought into the standard treatment regimen, and that's gemcitabine, a drug that sees wide use for — as a matter of fact, it's prescribed more often than the drugs that carry approval for peripheral T cell lymphoma. So when a patient gets assigned by randomization to the control group, the investigator's own judgment would permit choosing among those three agents; so Aydin, honestly, I believe the main issue is simply reaching consensus on the trial design and what constitutes standard therapy. That said, given that two of those agents already hold approval for relapsed T cell lymphoma, and gemcitabine is the choice of most physicians, at least within the United States, my sense is that disagreements on this point will be minimal. In addition, for trials of this type—several have been conducted previously—median PFS generally comes in at roughly three to four months. As a result, I'd say our sense of how the control arm will perform is fairly solid.
Aydin Huseynov
analystSo it's kind of a historical 3 to 4 months compared to 20 months that you've demonstrated until now. But regarding ORR, the rough calculations so far suggest 46%, or approximately that, within the ALC above 900 group for your drug. However, could you remind us what the historical ORR is for chemotherapy and the approved drug?
Richard Miller
executive25%, with very brief responses. One of the other — yes, by the way, the 40%, 50% response rate we're observing, the PRs, I'm confident those PRs are still responding, for example, as you saw some of that data recently. So obviously, some of that might change over time. So the ORR for the standard agents, as I noted earlier, sits at roughly 25%. That figure tends to hold up across studies. Responses don't last long. Beyond that, these control agents come with real drawbacks — administering them is quite hard, and they carry heavy toxicity. Take Belinostat, which is one of the approved options: you give it as an IV infusion across 5 consecutive days, repeated every 3 weeks. Then there's Pralatrexate, an injection given weekly — I believe 6 weeks out of 7 — but it demands extremely careful management of vitamin B12 and folate metabolism, with dosing 10 days before and 10 days after. That's a considerable burden, and these drugs bring substantial side effects: bone marrow suppression — meaning nausea, vomiting, bone marrow suppression — and none of that has shown up in our experience. One more thing worth noting: we're also going to track quality of life as an endpoint. PFS, of course, remains the main one we're measuring against, while the secondary ones include response rate, overall survival, how long responses last, and a quality of life evaluation too.
Aydin Huseynov
analystRichard, considering how hard it is to enroll patients and to administer this chemotherapy drug, do you think the FDA would suggest a 2:1 randomization?
Richard Miller
executiveSorry, could you say that again?
Aydin Huseynov
analystWhy suggest randomizing at a ratio of 2:1 rather than 1:1?
Richard Miller
executiveThat isn't something I'd anticipate, no. My feeling is that they wouldn't take that route, since to start with, a 1:1 design carries greater statistical power, and crossover is going to be permitted. That means those in the control group, once their disease advances, are able to switch over and receive the treatment.
Aydin Huseynov
analystRichard, congrats on the update, and congrats on the extra responses.
Rosemary Li
analystRosemary here, filling in for Li. We have just 2. Regarding 818, you brought up its potential in immune diseases too — so do you intend to produce some preliminary data in that area, or might you instead head straight toward securing a partner for those indications? Then, as for ciforadenant, the timeline appears to have moved somewhat. Could you give us a bit of insight into why? Is it because of enrollment, or simply a desire for longer follow-up, or something else?
Richard Miller
executiveThe first question was...
Rosemary Li
analystAnd what about 818 in immune diseases?
Richard Miller
executiveSure. We're pretty excited about what 818 can do in cancer. If you haven't checked out the AACR data yet, you really should — there are some genuinely striking results in there. On top of that, it's impressive to us that two separate scientific teams using animal models have shown that either genetic blockade of ITK or blocking it with our drug can strengthen anti-tumor responses. So right now we're concentrating hard on T cell lymphoma as the first target, with solid tumors coming next. In fact, a few medical centers have already expressed strong interest in launching a solid tumor study with 818. So that's going to come ahead of the immune diseases, because my view is that we clearly already have clinical data in that area. There's a lot we understand about it, and when it comes to getting a product approved and the path for development, I'd say oncology is a bit more straightforward for us. On the immune disease side, we're still considering whether we'll advance into those with 818 later this year. With that said, my sense is it will depend on how far we get in the cancer space. There's one additional point worth noting: we've got a number of back-up compounds, or next-generation compounds, for 818 that block ITK through somewhat different mechanisms. Some of those have a chemical structure that's fairly similar. Several of these compounds possess distinct chemical makeups, yet our ongoing research into these ITK inhibitors has shown something quite intriguing — namely, how much control we have over tuning their biologic characteristics. Looking ahead, I suspect we'll be able to engineer medications that are tailored even more precisely toward particular autoimmune conditions. Turning to what you asked about ciforadenant — there's no deceleration at all; the work continues. I'm not sure what prompted that question, but frontline kidney cancer patients are being enrolled by MD Anderson. Everything related to that will be reviewed when we convene at ASCO. Additional sites are joining as well. This is an open-label study, and the primary measure we're looking at is complete responses, or CRs, along with what we refer to as deep partial responses. We'll be able to get a sense of it — according to MD Anderson data published in the literature, CRs plus deep PRs occur at roughly 30%. So what we'd want to observe is a rate above 30% for CR and deep PR; and incidentally, complete responses alone make up only about 10%. That means even seeing a small number of CRs would be quite encouraging as well. And lastly, a few words about cifo and combining it with ipi/nivo — the reason for doing that wasn't simply to tack on another drug. This came out of a paper we put out in 2018. That work demonstrated that the immunobiology is set up in a way where blocking adenosine A2 pairs extremely well with anti-CTLA-4 treatment. There are reasons behind that, and I could walk through them at another point. But I'd also call that a novel biology — meaning it isn't simply one plus one making two. The way I see it, one plus one adds up to three.
Jerry Gong
analystJerry Gong here, filling in for Mara Goldstein. Nice work on the updates. So to start, regarding those 19 evaluable CPI-818 patients — could you share what the typical scan count per patient has been? And are all 6 of the additional efficacy evaluable patients receiving the 200 milligram dose?
Richard Miller
executiveScan count? You're asking about the typical scan count? What exactly do you mean? Scanning happens for patients once every 2 to 3 months.
Jiayuan Gong
analystFor the 19 efficacy evaluable patients, what would you say the median duration is — the amount of time they've spent in the study?
Richard Miller
executiveRight now I don't have the median duration of therapy available offhand. That said, if you check our previous conference call, a waterfall plot and a swimmer plot were included there. Take a look at that, Jerry, and you'll find specifics about how long those individuals have remained on therapy. If I were to estimate at this moment — and again, that figure isn't in front of me — 6 months or longer, though quite a few patients remain on therapy, PRs among them. In fact, I believe — it's returning to me now. One moment. Among patients in our study, those who have stayed on therapy beyond 6 months represent roughly 65%. Which suggests, I suppose, that the median would exceed that. Still, I'd point you to the data from our prior call.
Jiayuan Gong
analystGot it. So, I want to check — those 6 more patients who can be assessed for efficacy, plus everyone else who's still in the trial, is every one of them receiving the new 200 milligram dose?
Richard Miller
executiveThat's correct.
Jiayuan Gong
analystregarding those 5 patients who haven't had a baseline scan yet, could you tell us their ALC numbers?
Richard Miller
executivemy understanding is every one of them sits above 900; we began putting that into practice — right, all of them are over 900, since we kicked off doing that a few months back, in December if I recall correctly.
Jiayuan Gong
analystAnd I've got one last thing to ask; this continues from — or rather it's a follow-up on what was asked about ciforadenant before. By the time this year wraps up, from how many patients do you anticipate being in a position to share data?
Richard Miller
executiveGiven a bit of follow-up, over 10.
Jiayuan Gong
analystCongratulations once more on the update.
Roger Song
analystOne short question — regarding the Phase 3 818 trial in TCL, since we understand PFS will serve as the primary endpoint, could you potentially take an internal peek at ORR or other endpoints for early fighting or an interim data look? And on the solid tumor plan, given this AACR data, is there any timeline for the clinical plan there?
Richard Miller
executiveYes, we do intend to conduct an interim analysis of the data and assess response rate, in line with recent FDA guidelines on accelerated approval. I won't promise anything on that front; the reason being that median time to progression among controls is so brief that I'm uncertain there's much of a time gap between looking early for response rate and waiting for the final event-driven endpoint. Are you with me?
Roger Song
analystOkay, I understand.
Richard Miller
executiveWhether it truly changes much, I can't say for certain, though naturally we'd examine it — plus that's yet another item we'd need to talk over with the FDA. Still, my sense is that with this specific illness, the impact is fairly minimal, since the scheduling wouldn't shift all that much. Everything's relative, after all. Perhaps we're talking about a gap of just several months. Though I suppose that gap might end up mattering. As for your solid tumor question, at this point we haven't settled on any firm timeline for launching a trial in that area. However, we've held discussions regarding conditions such as kidney cancer, lung cancer, and melanoma, and we're examining the drug's performance in patients who are resistant to PD-1, for instance. On the positive side, an enormous number of individuals—thousands upon thousands—have been given anti-PD-1 and PD-L1 treatments. On the negative side, many of those patients develop resistance. Eventually, treatment stops working for most of them, whether because they never had a response in the first place or because the disease comes back. That's why understanding what drives resistance is something we're especially focused on, and those conversations are still underway. As I said during my presentation, it's clear that our immediate priority is the T cell lymphoma program, and we're working to advance it as fast as we can.
Richard Miller
executiveAppreciate it, operator, and thanks to all of you for joining us today. We're eager to bring you news down the road about how things are coming along. Thanks once more. Goodbye.
Operator
operatorThat brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.